Table 4.
ADCs against BCMA in clinical development.
| Drug | Target | Manufacturer | Therapeutic format and Mechanism of action | Dose | Dose schedule | Clinical outcome in Monotherapy | Reference |
|---|---|---|---|---|---|---|---|
| Belantamab (former GSK2857916) | BCMA | GSK | mAb: afucosylated IgG1 humanized αBCMA linker: non-cleavable, protease resistant payload: MMAF | 3.4 mg/kg | 30–60 min I.V. infusions every 3 weeks | RRMM ORR 60% | (159) |
| 2.5 mg/kg | RRMM ORR 31% | (160) | |||||
| AMG224 | BCMA | Amgen | mAb: IgG1 linker: not cleavable payload: mertansine | Phase I dose-escalation study, | 60 min I.V. infusions every 3 weeks | RRMM ORR 23% | (161) |
| 30–300 mg | |||||||
| MEDI2228 | BCMA | AstraZeneca | mAb: IgG1 linker: valine-alanine protease cleavable payload: tesirine | Phase I dose-escalation study | I.V. infusions every 3 weeks | RRMM ORR 66% at 0.14 mg/kg dose (N = 41) | (162) |
| 0.0125–0.20 mg/kg |